In a video interview with CURE, Dr. Elizabeth K. Lee explained that how a treatment affects daily life matters as much as how well it works.
|Articles|April 6, 2016
Mary Bohn on the Landscape of Multiple Myeloma Treatment
Author(s)Mary Bohn
Mary Bohn, RN, OCN, a nurse at Froedtert Hospital in Milwaukee, Wisconsin, discusses the landscape and side effects of treatment for patients with multiple myeloma.
Advertisement
Mary Bohn, RN, OCN, a nurse at Froedtert Hospital in Milwaukee, Wisconsin, discusses the landscape and side effects of treatment for patients with multiple myeloma. Bohn was one of our
Advertisement
Related to this article
Dr. Neel Chudgar of Montefiore Einstein answers the most searched questions about lung cancer surgery, including risks, recovery and recurrence.
Rinatabart sesutecan shrank tumors in 45.9% of patients with platinum-resistant ovarian cancer in a phase 2 study, with responses lasting a median of 12.1 months.
In a Johns Hopkins study, 64% of African American patients with myeloma received bone-modifying drugs in their first year, compared with 77% of White patients.
Six-year PERSEUS results show 81% of newly diagnosed, transplant-eligible myeloma patients had no cancer progression, with many stopping Darzalex.
A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.
Advertisement
Advertisement
Trending on CURE
1
Why PSA Monitoring Matters After a Prostate Cancer Diagnosis
2
ESMO 2026 Preview: 5 Late-Breaking Trials Patients Should Watch
3
What Breast Cancer Awareness Month Leaves Out
4
Who Should Get Genetic Testing After a Cancer Diagnosis?
5